Country, language and currency
- Social bookmarks:
- Testimonials
-
Thank you for the complimentary pack of
Sildenafil Citrate I'll be sure to put them to good use.
Read more »
-
- MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth ... - GenomeWeb
- MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth
- NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay - EON: Enhanced Online News (press release)
- NanoString Initiates Second Clinical Validation Study for Breast Cancer AssayEON: Enhanced Online News (press release)The ABCSG8 study, initiated in 1996, demonstrated that compared to treatment with tamoxifen alone, sequential adjuvant treatment with tamoxifen followed by anastrozole in postmenopausal women with hormone receptor-positive early-stage breast cancer
- Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - SYS-CON Media (press release)
- Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality ReductionSYS-CON Media (press release)Drugs covered include: Abiraterone acetate (Zytiga), Afatinib (Tomtovok), Afimoxifene (TamoGel), Albumin-bound paclitaxel (Abraxane), Anastrozole (Arimidex), Apatinib, Bevacizumab (Avastin), Bosutinib, Capecitabine (Xeloda), Cediranib,
- Norton Rose Group | Pharma in brief - Canada: Federal Court of Appeal upholds ... - Linex Legal (press release) (registration)
- Norton Rose Group | Pharma in brief - Canada: Federal Court of Appeal upholds
- An object clause is not necessarily determinative of the promise of the patent - Lexology (registration)
- An object clause is not necessarily determinative of the promise of the patentLexology (registration)Analysis – The `420 Patent relates to (substituted-aralkyl) – heterocyclic compounds, including anastrozole, and in particular, to such compounds which are useful as inhibitors of the enzyme aromatase
